Last reviewed · How we verify

BioVersys SAS — Portfolio Competitive Intelligence Brief

BioVersys SAS pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BV100 (300 mg) BV100 (300 mg) phase 3 Benzoxaborole antibiotic Leucyl-tRNA synthetase (LeuRS) Infectious Disease
MEROPENEM 2 grams TID MEROPENEM 2 grams TID phase 3 Carbapenem antibiotic Penicillin-binding proteins (PBPs) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  4. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 shared drug class
  5. Institute of Liver and Biliary Sciences, India · 1 shared drug class
  6. National University of Singapore · 1 shared drug class
  7. Unity Health Toronto · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BioVersys SAS:

Cite this brief

Drug Landscape (2026). BioVersys SAS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioversys-sas. Accessed 2026-06-10.

Related